104 research outputs found

    IMPACTS OF INCORPORATING LAND EXCHANGES BETWEEN FORESTRY AND AGRICULTURE IN SECTOR MODELS

    Get PDF
    The forest and agriculture sectors are linked by having a portion of their land bases suitable for use in either sector. A substantial part of the southern land base is suitable for either forestry or agriculture use, with most of forestation on U.S. agriculture land in the South. We examine how land exchanges between forestry and agriculture are influenced by specific federal conservation and farm support policies, including changes in the Conservation Reserve Program. Reallocation of land is a significant part of the sectors' responses to the policies, along with intensification of timber management on existing southern forests.Agriculture, Conservation, Forest sector, Land use, Projections, Land Economics/Use,

    The Combined Optimization of Log Bucking and Sawing Strategies

    Get PDF
    Determination of optimal bucking and sawing policies is linked in a common model. The core of this model is a linear program (LP) that selects stem bucking and log sawing policies to maximize profits given an input distribution of raw material. Product output is controlled by price-volume relationships that simulate product demand curves. The model uses a three stage solution process performed iteratively until identical solution bases are obtained. A variation of the Dantzig-Wolfe decomposition principle is used, linking the three models through the use of the Lagrange multipliers from the LP. The procedure is demonstrated for a sample sawmill. The revenue gain from using the policies suggested by the integrated model over those found by the bucking and sawing programs working separately was found to be 26%-36%

    ECONOMIC IMPACTS OF CLIMATE CHANGE ON SOUTHERN FORESTS

    Get PDF
    A multiperiod regional mathematical programming model is used to evaluate the potential economic impacts of global climatic change on the southern U.S. forestry sector. Scenarios for forest biological response to climate change are developed for small and large changes in forest growth rates. Resulting changes in timber supply have economic impacts on producers and consumers in forest products markets, both nationally and regionally. Conclusions include outer dimensions of global climate change impacts and potential effects of smaller biological responses on the forestry sector both nationally and in the U.S. South. Relative impacts are found to be larger for producers than for consumers, and southern producers experience relatively greater changes in economic welfare.Resource /Energy Economics and Policy,

    Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry

    Get PDF
    Background and purpose: Prospectively collected data comparing the safety and effectiveness of individual non-vitamin K antagonists (NOACs) are lacking. Our objective was to directly compare the effectiveness and safety of NOACs in patients with newly diagnosed atrial fibrillation (AF). Methods: In GLORIA-AF, a large, prospective, global registry program, consecutive patients with newly diagnosed AF were followed for 3 years. The comparative analyses for (1) dabigatran vs rivaroxaban or apixaban and (2) rivaroxaban vs apixaban were performed on propensity score (PS)-matched patient sets. Proportional hazards regression was used to estimate hazard ratios (HRs) for outcomes of interest. Results: The GLORIA-AF Phase III registry enrolled 21,300 patients between January 2014 and December 2016. Of these, 3839 were prescribed dabigatran, 4015 rivaroxaban and 4505 apixaban, with median ages of 71.0, 71.0, and 73.0 years, respectively. In the PS-matched set, the adjusted HRs and 95% confidence intervals (CIs) for dabigatran vs rivaroxaban were, for stroke: 1.27 (0.79–2.03), major bleeding 0.59 (0.40–0.88), myocardial infarction 0.68 (0.40–1.16), and all-cause death 0.86 (0.67–1.10). For the comparison of dabigatran vs apixaban, in the PS-matched set, the adjusted HRs were, for stroke 1.16 (0.76–1.78), myocardial infarction 0.84 (0.48–1.46), major bleeding 0.98 (0.63–1.52) and all-cause death 1.01 (0.79–1.29). For the comparison of rivaroxaban vs apixaban, in the PS-matched set, the adjusted HRs were, for stroke 0.78 (0.52–1.19), myocardial infarction 0.96 (0.63–1.45), major bleeding 1.54 (1.14–2.08), and all-cause death 0.97 (0.80–1.19). Conclusions: Patients treated with dabigatran had a 41% lower risk of major bleeding compared with rivaroxaban, but similar risks of stroke, MI, and death. Relative to apixaban, patients treated with dabigatran had similar risks of stroke, major bleeding, MI, and death. Rivaroxaban relative to apixaban had increased risk for major bleeding, but similar risks for stroke, MI, and death. Registration: URL: https://www.clinicaltrials.gov. Unique identifiers: NCT01468701, NCT01671007. Date of registration: September 2013
    corecore